Biodistribution and Radiation Dosimetry for the Novel SV2A Radiotracer [18F]UCB-H: First-in-Human Study

Molecular Imaging and Biology

Volumn 17, Issue 4, 2015, Pages 557-564

  Bretin, F ^a   Bahri, M A ^a   Bernard, C ^c   Warnock, G ^a   Aerts, J ^a   Mestdagh, N ^b   Buchanan, T ^b   Otoul, C ^b   Koestler, F ^b   Mievis, F ^a   Giacomelli, F ^a   Degueldre, C ^a   Hustinx, R ^c   Luxen, A ^a   Seret, A ^a   Plenevaux, A ^a   Salmon, E ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UCB PHARMA   (Belgium)

^c UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Brain; Human dosimetry; PET; Radiotracer; SV2A; Translational

Indexed keywords

BETA1 INTEGRIN; RADIOPHARMACEUTICAL AGENT; SYNAPTIC VESICLE GLYCOPROTEIN 2A; UCB H F 18; UNCLASSIFIED DRUG; 2 PYRROLIDONE DERIVATIVE; FLUORINE; MEMBRANE PROTEIN; NERVE PROTEIN; PYRIDINE DERIVATIVE; SV2A PROTEIN, HUMAN; UCB-H COMPOUND;

ADULT; AGED; ARTICLE; BLADDER WALL; BRAIN; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG TISSUE LEVEL; GALLBLADDER; HEART; HUMAN; HUMAN EXPERIMENT; LIVER; LUNG; MALE; NORMAL HUMAN; PET-CT SCANNER; PRIORITY JOURNAL; SPLEEN; ANIMAL; COMPUTER ASSISTED TOMOGRAPHY; METABOLISM; MIDDLE AGED; MOUSE; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; RADIOMETRY; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

MUS;

ANIMALS; FLUORINE RADIOISOTOPES; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MIDDLE AGED; NERVE TISSUE PROTEINS; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; PYRROLIDINONES; RADIOMETRY; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 84937519108     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-014-0820-6     Document Type: Article

References (36)

1. Jahn R, Fasshauer D (2012) Molecular machines governing exocytosis of synaptic vesicles. Nature 490:201–207
2. Janz R, Südhof TC, Hammer RE et al (1999) Essential roles in synaptic plasticity for synaptogyrin I and synaptophysin I. Neuron 24:687–700
3. Crevecoer J, Kaminski RM, Rogister B et al (2014) Expression pattern of synaptic vesicle protein 2 (SV2) isoforms in patients with temporal lobe epilepsy and hippocamal sclerosis. Neuropathol Appl Neurobiol 40:191–204
4. Nowack A, Yao J, Custer KL, Bajjalieh SM (2010) SV2 regulates neurotransmitter release via multiple mechanisms. Am J Physiol Cell Physiol 299:C960–C967
5. Bajjalieh SM, Frantz GD, Weimann JM et al (1994) Differential expression of synaptic vesicle protein 2 (SV2). J Neurosci 14:5223–5235
6. Janz R, Sudhof TC (1999) SV2C is a synaptic vesicle protein with an unusually restricted localization: anatomy of a synaptic vesicle protein family. Neuroscience 94:1279–1290
7. 2+ regulators in neurotransmitter release. Neuron 24:1003–1016
8. Lynch BA, Lambeng N, Nocka K et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci U S A 101:9861–9866
9. Bakker A, Krauss GL, Albert MS et al (2012) Reduction of hippocampal hyperactivity improves cognition in amnestic mild cognitive impairment. Neuron 74:467–474
10. Patsalos PN (2000) Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 85:77–85
11. 11C-Levetiracetam: a potential marker for PET imaging of SV2A expression. ACS Med Chem Lett 5:1152–1155
12. 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain. J Nucl Med 55:1336–1341
13. 18F]UCB-H. Eur J Nucl Med Mol Imaging Res 3:35–42
14. Verbruggen A, Coenen HH, Deverre JR et al (2008) Guideline to regulations for radiopharmaceuticals in early phase clinical trials in the EU. Eur J Nucl Med Mol Imaging 35:2144–2151
15. Siegel JA, Thomas SR, Stubbs JB, et al. (1999) MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 4037S-61S
16. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS (2007) Performance of Philips Gemini TF PET/CT scanner with special consideration for its time-of-flight imaging capabilities. J Nucl Med 48:471–480
17. Feldkamp LA, Davis LC, Wress JW (1984) Practical cone-beam algorithm. J Opt Soc Am A Opt Image Sci Vis 1:612–619
18. Wang W, Hu Z, Gualtieri EE et al (2006) Systematic and distributed time-of-flight list mode PET reconstruction [proceeding]. IEEE Nucl Sci Symposium Conference Record 3:1715–1722
19. Boellaard R, Hristova I, Ettinger S et al (2013) EARL FDG-PET/CT accreditation program: feasibility, overview and results of first 55 successfully accredited sites [abstract]. Soc Nucl Med Ann Meet Abs 54:2052
20. Eckerman KF, Cristy M, Ryman JC (1996) The ORNL mathematical phantom series. Oak Ridge National Laboratory, Oak Ridge
21. Stabin MG, Sparks RB, Crowe E (2005) OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 46:1023–1027
22. Stabin MG (2008) Steps in dose calculations. In: Fundamentals of nuclear medicine dosimetry. Springer, pp 77-118
23. Laymon CM, Narendran R, Mason NS et al (2011) Human biodistribution and dosimetry of the PET radioligand [11C] flumazenil (FMZ). Mol Imag Biol 14:115–122
24. Bullich S, Slifstein M, Passchier J et al (2011) Biodistribution and radiation dosimetry of the glycine transporter-1 ligand 11C-GSK931145 determined from primate and human whole-body PET. Mol Imag Biol 13:776–784
25. 18F]-FEPPA, to image translocator protein (18 kDa). Mol Imag Biol 15:353–359
26. ICRP (1991) 1990 Recommendations of the international commission on radiological protection. In: ICRP Publication 60. Pergamon, New York
27. ICRP (2007) ICRP publication 103. Ann ICPR 37:1–332
28. Eberlein U, Bröer JH, Vandevoorde C et al (2011) Biokinetics and dosimetry of commonly used radiopharmaceuticals in diagnostic nuclear medicine—a review. Eur J Nucl Med Mol Imaging 38:2269–2281
29. Deloar HM, Fujiwara T, Shidahara M et al (1998) Estimation of absorbed dose for 2-[F-18] fluoro-2-deoxy-D-glucose using whole-body positron emission tomography and magnetic resonance imaging. Eur J Nucl Med Mol Imaging 25:565–574
30. Waxman AD, Herholz K, Lewis DH, et al. (2009) Society of nuclear medicine procedure guideline for FDG PET brain imaging. Soc Nucl Med (Version 1.0)
31. Code of Federal Regulations (2014) Drugs for human use, title 21, volume 5. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=361.1, FDA
32. Kirschner AS, Ice RD, Beierwaltes WH (1975) Radiation dosimetry of 131I-19-iodocholesterol: the pitfalls of using tissue concentration data, the author’s reply. J Nucl Med 16:248–249
33. McParland BJ (2010) Nuclear medicine radiation dosimetry. In: The biodistribution I—preclinical. Springer, pp 519-532
34. 18F-FDG PET studies in mice. J Nucl Med 47:999–1006
35. Sakata M, Oda K, Toyohara J et al (2013) Direct comparison of radiation dosimetry of six PET tracers using human whole-body imaging and murine biodistribution studies. Ann Nucl Med 27:285–296
36. 11C-labeled tracers for first-in-human studies. Eur J Nucl Med Mol Imaging 39:544–547